Radelumin (18F-PSMA-1007) is a radioactive diagnostic agent used for Positron Emission Tomography (PET).
It helps in imaging prostate-specific membrane antigen (PSMA)-positive lesions in adult patients. This is particularly useful for suspected recurrence of prostate cancer after primary curative therapy, based on increasing serum prostate-specific antigen (PSA) levels. Additionally, it is also used for the primary staging of patients with high-risk prostate cancer prior to primary curative therapy. See SmPC for the full indication and product information (https://abx.de/products/medicinal-products/product-information-radelumin-1).
Radelumin contains 18F-PSMA-1007 as the active substance and is administered by intravenous injection.
Availability: Radelumin is available on Monday, Wednesday, Thursday, and Friday.
Other products
Interested in our products?
Contact us to discuss the possibilities.